Antineutrophil cytoplasmatic antibodies in patients with premature atherosclerosis: Prevalence and association with risk factors

Journal of Internal Medicine

Volumn 251, Issue 1, 2002, Pages 29-34

  Van Haelst, P L ^a   Asselbergs, F W ^a   Van Doormaal, J J ^a,b   Veeger, N J G M ^a   May, J F ^a   Holvoet, P ^c   Gans, R O B ^b   Cohen Tervaert, J W ^b,d  

^a Department of Cardiology ^*  (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Antineutrophil cytoplasmatic antibodies; Autoimmunity; Inflammation; Premature atherosclerosis

Indexed keywords

C REACTIVE PROTEIN; LOW DENSITY LIPOPROTEIN; MALONALDEHYDE; SERUM AMYLOID A;

ADULT; ARTICLE; ATHEROSCLEROSIS; AUTOIMMUNITY; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE SEVERITY; FEMALE; HUMAN; HYPOTHESIS; INFLAMMATORY DISEASE; MALE; OXIDATION; PERIPHERAL VASCULAR DISEASE; PREMATURITY; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR;

ADULT; ANALYSIS OF VARIANCE; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; ARTERIOSCLEROSIS; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; MALE; MIDDLE AGED; PREVALENCE; REGRESSION ANALYSIS; RISK FACTORS; STATISTICS, NONPARAMETRIC;

EID: 0036200633     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2796.2002.00920.x     Document Type: Article

References (30)

1. Atherosclerosis - An inflammatory disease
2. Involvement of the immune system in human atherogenesis: Current knowledge and unanswered questions
3. Fatty streak formation occurs in human fetal aortas and is greatly enhanced by maternal hypercholesterolemia. Intimal accumulation of low density lipoprotein and its oxidation precede monocyte recruitment into early atherosclerotic lesions
4. Clinical factors and angiographic features associated with premature coronary artery disease
5. Risk factors for premature atherosclerosis
6. Antibodies against endothelial cells and cardiolipin in young patients with peripheral atherosclerotic disease
7. Autoantibodies against oxidized low-density lipoprotein and cardiolipin in patients with coronary heart disease
8. Association of serum antibodies to heat-shock protein 65 with carotid atherosclerosis: Clinical significance determined in a follow-up study
9. Autoantibodies against oxidized low density lipoprotein in patients with angiographically verified coronary artery disease
10. Accelerated atherosclerosis and coronary disease in SLE
11. Antibodies against granule proteins activate neutrophils in vitro
12. Occurrence of autoantibodies to human leucocyte elastase in Wegener's granulomatosis and other inflammatory disorders
13. Autoantibodies against myeloid lysosomal enzymes in crescentic glomerulonephritis
14. Malondialdehyde-modified low density lipoproteins in patients with atherosclerotic disease
15. SAA versus CRP serum levels in different inflammatory conditions, studied by ELISA using polyclonal anti-AA and monoclonal anti-SAA antibodies
16. A quantitative method for detecting deposits of amyloid A protein in aspirated fat tissue of patients with arthritis
17. Prevention of relapses in systemic lupus erythematosus
18. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa heart study
19. Autoimmunity in atherosclerosis: Lessons from experimental models
20. Are immunological mechanisms relevant for the development of atherosclerosis?
21. Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR project for ANCA assay standardization
22. Antibodies against oxidized LDL and carotid artery intima-media thickness in a healthy population
23. Lipoprotein(a) is an independent risk factor for myocardial infarction at a young age
24. Lipoprotein(a) levels in systemic lupus erythematosus
25. Elevated plasma lipoprotein(a) level and its association with impaired fibrinolysis in patients with antiphospholipid syndrome
26. Lipoprotein Lp(a) excess and coronary heart disease
27. Expression of adhesion molecules by lp(a): A potential novel mechanism for its atherogenicity
28. Atherosclerosis-related markers in systemic lupus erythematosus patients: The role of humoral immunity in enhanced atherogenesis
29. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein